ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc. (ALXO) is expected to report earnings on November 5, 2026, before the market open. The consensus earnings estimate is a loss of $0.15 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +1.0% since its last earnings release on August 6, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc.is a clinical-stage immuno-oncology company. It focuses on developing therapies for patients fighting cancer. The company's product candidate consist ALX148, which is in clinical stage. ALX Oncology Holdings Inc.is based in Burlingame, California.
Sector
Healthcare
Industry
Biotechnology